We are live on ! Find out more
Baillie Gifford & Co

Baillie Gifford & Co Portfolio holdings

AUM $110B
1-Year Est. Return 4.8%
 

Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.

This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
+4.8%
3 Year Est. Return
+123.53%
5 Year Est. Return
+125.55%
10 Year Est. Return
+1,754.37%
AUM
$179B
AUM Growth
-$942M
Cap. Flow
+$4.9B
Cap. Flow %
2.74%
Top 10 Hldgs %
37.48%
Holding
469
New
39
Increased
260
Reduced
115
Closed
23

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$3.05B
2
CPNG icon
Coupang
CPNG
+$1.02B
3
TTD icon
Trade Desk
TTD
+$941M
4
AFRM icon
Affirm
AFRM
+$795M
5
BILI icon
Bilibili
BILI
+$729M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$8.35B
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$1.34B
3
NIO icon
NIO
NIO
+$810M
4
META icon
Meta Platforms (Facebook)
META
+$804M
5
AMZN icon
Amazon
AMZN
+$792M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 31.68%
2 Healthcare 19.13%
3 Technology 16.8%
4 Communication Services 14.58%
5 Financials 5.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ZYXI
426
DELISTED
Zynex
ZYXI
$7K ﹤0.01%
481
BMRN icon
427
BioMarin Pharmaceuticals
BMRN
$12.4B
$6K ﹤0.01%
82
+8
+11% +$654
EXTR icon
428
Extreme Networks
EXTR
$3.15B
$6K ﹤0.01%
687
+99
+17% +$863
OXM icon
429
Oxford Industries
OXM
$552M
$6K ﹤0.01%
73
-9
-11% -$691
ATRI
430
DELISTED
Atrion Corp
ATRI
$6K ﹤0.01%
9
AFIB
431
DELISTED
Acutus Medical Inc
AFIB
$6K ﹤0.01%
424
+6
+1% +$135
AGX icon
432
Argan
AGX
$8.37B
$5K ﹤0.01%
103
FOLD
433
DELISTED
Amicus Therapeutics
FOLD
$5K ﹤0.01%
538
+3
+0.6% +$46
HRTX icon
434
Heron Therapeutics
HRTX
$92.9M
$5K ﹤0.01%
308
-18
-6% -$321
MDXG icon
435
MiMedx Group
MDXG
$633M
$5K ﹤0.01%
513
+29
+6% +$280
QTTB icon
436
Q32 Bio
QTTB
$464M
$5K ﹤0.01%
27
ALKS icon
437
Alkermes
ALKS
$8.25B
$4K ﹤0.01%
192
+37
+24% +$757
HCSG icon
438
Healthcare Services Group
HCSG
$1.53B
$4K ﹤0.01%
157
+4
+3% +$121
VRAY
439
DELISTED
ViewRay, Inc.
VRAY
$4K ﹤0.01%
911
+108
+13% +$525
AMRX icon
440
Amneal Pharmaceuticals
AMRX
$5.79B
$3K ﹤0.01%
452
-65
-13% -$360
AXDX
441
DELISTED
Accelerate Diagnostics
AXDX
$3K ﹤0.01%
42
+5
+14% +$507
AAOI icon
442
Applied Optoelectronics
AAOI
$11.5B
$2K ﹤0.01%
260
PBYI icon
443
Puma Biotechnology
PBYI
$454M
$2K ﹤0.01%
252
ICPT
444
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2K ﹤0.01%
101
+15
+17% +$418
CLVS
445
DELISTED
Clovis Oncology, Inc.
CLVS
$1K ﹤0.01%
92
-50
-35% -$335
ANET icon
446
Arista Networks
ANET
$238B
-1,568
Closed -$28K
EPAM icon
447
EPAM Systems
EPAM
$5.03B
-115
Closed -$41K
ETSY icon
448
Etsy
ETSY
$7.85B
-714
Closed -$127K
FARO
449
DELISTED
Faro Technologies
FARO
-446,108
Closed -$31.5M
B
450
Barrick Mining
B
$73.2B
-6,005
Closed -$137K

Similar funds

Baillie Gifford & Co's Q1 2021 Portfolio in Review

As of Q1 2021, Baillie Gifford & Co held 469 positions worth $179B, down 0.52% from $180B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Baillie Gifford & Co's Q1 2021 filing shows 39 new, 260 increased, 115 reduced and 23 closed positions. Its largest new stake was Coupang: 22,054,023 shares worth $1.09B. The largest sale was Tesla, an estimated $8.35B.

By sector, the portfolio is most concentrated in Consumer Discretionary at 32% of assets, down from 38% a quarter earlier, followed by Healthcare and Technology.

  • Baillie Gifford & Co's largest Q1 2021 buy was Coupang: 22,054,023 shares worth $1.09B.
  • Baillie Gifford & Co added most to Moderna in Q1 2021, an estimated $3.05B increase.
  • Baillie Gifford & Co's biggest Q1 2021 reduction was Tesla, cutting an estimated $8.35B.
  • Baillie Gifford & Co fully exited Stellantis in Q1 2021, selling an estimated $533M.
  • Baillie Gifford & Co's ten largest holdings make up 37% of its $179B portfolio in Q1 2021.
  • Baillie Gifford & Co opened 39 new positions and closed 23 in Q1 2021.
  • Baillie Gifford & Co's portfolio value fell 0.52% quarter-over-quarter to $179B.

Based on Baillie Gifford & Co's 13F filing for Q1 2021, filed 6 May 2021.